80 Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden (TMB) and clinical utility for predicting response to pembrolizumab
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |